Αρχική World News Targeted Radiation Reduces Pain from Cancer Metastases in the Spine

Targeted Radiation Reduces Pain from Cancer Metastases in the Spine

, by NCI Staff

An MRI shows a metastatic tumor (yellow arrow) in a patient’s spine.

Credit: Int J Surg Oncol November 2011. doi: 10.1155/2011/769753. CC BY 3.0.

Pain caused by cancer that has spread, or metastasized, to the spine is a major problem for many patients. New findings from a clinical trial indicate that, for some patients with painful spinal metastases from advanced cancer, a type of precise, high-dose radiation therapy may be a highly effective way to relieve that pain.

About a third of people in the clinical trial who received this form of radiation therapy, called stereotactic body radiation therapy, or SBRT, for spinal metastases were pain-free up to 6 months after treatment, compared with only about 15% of people who received conventional external beam radiation therapy to treat the pain.

“This is one way to help patients with metastatic disease in a tangible way: by reducing pain,” said Arjun Sahgal, M.D., of the Sunnybrook Health Sciences Center at the University of Toronto, who led the study and presented the results on October 26 at the 2020 Annual Meeting of the American Society for Radiation Oncology. 

These results cannot be applied to all people with spinal metastases, cautioned Jeffrey Buchsbaum, M.D., Ph.D., of NCI’s Radiation Research Program, who was not involved with the study. But for select people who have a limited number of tumors in the spine, “SBRT is a new standard of care,” he said.

A Painful Location

When cancer spreads from its original location, metastatic tumors can arise in many distant sites. Bone is a common site of metastasis for a number of cancer types. 

Unfortunately, once cancer cells take up residence in bone, pain can be a devastating side effect, as the growing tumor destroys the surrounding cells. For people who have metastatic tumors growing in the bones of the spine, “the pain can be insurmountable,” even with high doses of pain medication, Dr. Sahgal said.

Doctors may try radiation therapy to shrink these tumors and reduce the pain they cause. But conventional radiation therapy doesn’t effectively control pain in most people with spinal metastases, explained Dr. Sahgal. This is because the dose of radiation must be kept relatively low to avoid damaging the spinal cord itself, which can sit just millimeters away from a tumor.

In recent years, because it can more precisely target tumors, SBRT has come to be widely used for people with only a few, small metastatic tumors (known as oligometastatic cancer), including those in the spine, he added. Some studies have shown that if these few metastases can be successfully treated, patients may live for years or decades.

Because of their potentially good prognosis, people with oligometastatic cancer were thought to be more likely than people with advanced metastatic disease to benefit from SBRT, which is more expensive and has a higher risk of causing some types of damage in the spine than conventional radiation therapy, Dr. Sahgal explained. 

But the limitations of conventional radiation therapy as a palliative treatment for people with advanced cancer and spinal metastases eventually led researchers to wonder if SBRT might also be a better option for people with limited life expectancy. 

Boosting the Radiation Dose

A previous trial didn’t show a difference between SBRT and conventional radiation therapy in their ability to relieve spinal pain in people with three or fewer sites of spinal metastases. 

But there were several key differences between that trial and the current study, Dr. Sahgal explained. The previous trial used a lower dose of SBRT, given in a single session. The current study used a higher total dose of radiation for SBRTa dose high enough to potentially destroy (ablate) the metastases. SBRT was also given in two sessions, a process called fractionation.

In addition to the higher dose, laboratory experiments have suggested that fractionation itself may actually make radiation more effective at killing cancer cells, said Dr. Sahgal.

The new study also used a method to score pain that took into account the amount of pain medication needed by individual patients for relief, to make sure the effects of palliative radiation therapy weren’t masked by painkiller use. “This is a very robust way to show if we actually improve their outcomes,” he explained.

The new study included about 200 people with three or fewer spinal metastases in a concentrated area of the spine that were the sole source of their pain. None had measurable signs of instability in the bones of the spine, which would increase the risk of fracture and make it harder to assess pain.

Half of the participants received the two sessions of SBRT, for a total dose of 24 Gy (a Gy, short for Gray, is the standard measurement of radiation dose). The other half received 20 Gy of standard radiation—the maximum considered to be safe when using conventional radiation therapy—split over five sessions. 

Double the Pain Relief

Three months after treatment, 35% of people in the SBRT group reported that their spinal pain was gone, compared with 14% of the people who received conventional radiation therapy. 

This benefit was sustained over time. At 6 months, 32% of people in the SBRT group were still pain-free, compared with 16% of the conventional radiation group. 

“That’s a major gain for these patients,” said Dr. Sahgal. “The relief that they were getting continued in the longer term.”

Measurements of spinal stability after 6 months were about the same in both groups. The risk of compression fractures was also similar in both groups, and the risk of serious fractures was minimal, the researchers reported. There were also no reports of damage to the spinal cord caused by the radiation treatments.

Further Pushing the Limits

“It isn’t surprising that a higher radiation dose is better, but [modern] SBRT technology is what allowed that dose to be delivered safely,” said Dr. Buchsbaum. “In short, careful patient selection and a higher dose yielded the expected results.

“Moving forward, it’s important that practitioners apply this treatment approach on patients with limited spinal metastases, and not the general population of all patients with spinal metastases,” he added.

“This isn’t for the patient who has pain everywhere [in the spine], which is unfortunately the majority of patients,” agreed Dr. Sahgal. “But if you have a defined region of metastatic disease in the spine, and you can pinpoint the pain to that region, that’s going to be who benefits.”

His team hopes to test if further pushing the limits of spinal SBRT could help a greater number of patients with limited spinal metastases. They plan to test both 28 Gy in two fractions, and an “ultra-high” single dose of 24 Gy, to see if either regimen can reduce pain in more patients while maintaining the level of safety seen in the current trial.

They are also designing trials to see if SBRT can eliminate pain from bone metastases in other parts of the body, such as the arms or the ribs, Dr. Sahgal explained.

“There’s data that suggests it will, but we need to prove it,” he said. If it can, “that will change the game overall for patients with bone metastases.”



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...